| PRECLINICAL | evidence | The Drug Update: Recent drug approvals, summer 2025 edition. | Zepbound | — | 2025-08-01 |
| PRECLINICAL | evidence | Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. | Mounjaro | — | 2025-08-01 |
| PRECLINICAL | evidence | Evaluating Thyroid Cancer Risk in Glucagon-like Peptide-1 Analog Users With Thyroid Nodules. | Mounjaro | Glycemic control | 2025-08-01 |
| PRECLINICAL | evidence | Nonmechanical Small Bowel Obstruction in a Patient on Zepbound Without a Surgical History: A Case Report. | Zepbound | — | 2025-08-01 |
| PRECLINICAL | evidence | The use of tirzepatide to successfully treat persistent genital arousal disorder/genitopelvic dysesthesia: a case report. | Tirzepatide | — | 2025-08-01 |
| PRECLINICAL | evidence | Tirzepatide gains US Food and Drug Administration approval for the management of obstructive sleep apnea: Implications for oral health care providers. | Zepbound | Sleep quality | 2025-08-01 |
| PRECLINICAL | evidence | Long-acting hydrogel-based depot formulations of tirzepatide and semaglutide for the management of type 2 diabetes and weight. | Mounjaro | — | 2025-07-05 |
| PRECLINICAL | evidence | Use of tirzepatide (Mounjaro) in type 2 diabetes management: an overview. | Mounjaro | Glycemic control | 2025-07-02 |
| PRECLINICAL | evidence | Animal models for development of anti-obesity drugs in the age of GLP-1 agents. | Mounjaro | Weight & fat loss | 2025-07-01 |
| PRECLINICAL | evidence | Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom. | Mounjaro | — | 2025-06-23 |
| PRECLINICAL | evidence | Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types. | Mounjaro | Glycemic control | 2025-06-01 |
| PRECLINICAL | evidence | When the Transition Goes Wrong: A Rare Case of Diabetic Ketoalkalosis After Transitioning to Tirzepatide in Insulin-dependent Type 2 Diabetes. | Mounjaro | — | 2025-06-01 |
| PRECLINICAL | evidence | A Probable Case of Tirzepatide-Induced Acute Pancreatitis. | Mounjaro | — | 2025-06-01 |
| PRECLINICAL | evidence | Drugs for chronic heart failure. | Mounjaro | — | 2025-05-26 |
| PRECLINICAL | evidence | Bariatric Surgery and GLP-1/GIP Medications for the Treatment of Obstructive Sleep Apnoea: A Comprehensive Review. | Zepbound | Weight & fat loss | 2025-05-23 |
| PRECLINICAL | evidence | Tirzepatide-Induced Weight Loss and Normalization of Glycemia With Nerve Regeneration in Type 2 Diabetes: A Case Report. | Tirzepatide | — | 2025-05-01 |
| PRECLINICAL | evidence | Tirzepatide-induced lichen planus pigmentosus. | Tirzepatide | — | 2025-05-01 |
| PRECLINICAL | evidence | Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data. | Mounjaro | — | 2025-05-01 |
| PRECLINICAL | evidence | Is global interest in fasting, intermittent fasting and the liver shifting? | Mounjaro | — | 2025-04-27 |
| PRECLINICAL | evidence | Euglycemic Ketoacidosis in a Non-diabetic Patient After Tirzepatide Use: A Cautionary Tale. | Mounjaro | — | 2025-04-01 |
| PRECLINICAL | evidence | A Case of Pulmonary Hemorrhage, Supratherapeutic International Normalized Ratio (INR), and Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: Unmasking a Potential Link to Tirzepatide. | Mounjaro | — | 2025-03-01 |
| PRECLINICAL | evidence | Tirzepatide (Zepbound) for obstructive sleep apnea. | Zepbound | — | 2025-02-17 |
| PRECLINICAL | evidence | CORRECTION: Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide? | Mounjaro | — | 2025-02-07 |
| PRECLINICAL | evidence | Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide? | Mounjaro | — | 2025-02-03 |
| PRECLINICAL | evidence | Clinical Data Mega-Collection of Obesity and Obesity-Related Trials: Primary Inclusion Criteria from All Studies and Highlights of Clinical Efficacy Analysis of GLP-1 Drugs. | Zepbound | — | 2025-01-26 |
| PRECLINICAL | evidence | Longitudinal Analysis of Obesity Drug Use and Public Awareness. | Zepbound | Weight & fat loss | 2025-01-02 |
| PRECLINICAL | evidence | Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss. | Tirzepatide | Weight & fat loss | 2025-01-01 |
| PRECLINICAL | evidence | Health Beliefs and Obesity Bias as Determinants of Attitudes Toward the Rising Tides of GLP-1 Medications: Mounjaro and Ozempic. | Mounjaro | — | 2025-01-01 |
| PRECLINICAL | evidence | Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Distinct effects of semaglutide and tirzepatide on metabolic and inflammatory gene expression in brown adipose tissue of mice fed a high-fat, high-fructose diet. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Pharmacotherapy for Obesity: Recent Updates. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | When New Therapies Meet Old Challenges: Tirzepatide-Warfarin Interaction in A Mechanical Mitral Valve Patient. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Atherosclerotic features in patients with heart failure. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | GIP/GLP-1RA as adjunctive to automated insulin delivery in adults with Type 1 diabetes (the AID-JUNCT trial): Study protocol for a prospective, randomized, clinical trial. | Tirzepatide | Glycemic control | 2025-01-01 |
| PRECLINICAL | evidence | Management of Hypoglycemia Using Continuous Glucose Monitoring During Tirzepatide Initiation or Uptitration When Used in Addition to Other Glucose-Lowering Agents. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review. | Tirzepatide | Glycemic control | 2025-01-01 |
| PRECLINICAL | evidence | Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon. | Tirzepatide | Weight & fat loss | 2025-01-01 |
| PRECLINICAL | evidence | Association of tirzepatide and the risk of suicide in a real-world cohort. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Validation of a Questionnaire for Assessing the Emotional Impact of Treatment for Type 2 Diabetes. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Immunometabolic crossroads: infections as bidirectional modulators in diabetes and metabolic syndromes. | Tirzepatide | Glycemic control | 2025-01-01 |
| PRECLINICAL | evidence | Tirzepatide alleviates non-alcoholic fatty liver disease by regulating lipid metabolism through activation of the AMPK/NF-kappaB signaling pathway. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Benign small bowel pneumatosis intestinalis: report of a rare adverse effect of tirzepatide. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review. | Tirzepatide | — | 2025-01-01 |
| PRECLINICAL | evidence | In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists. | Mounjaro | — | 2024-12-23 |